Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
David Henry MD
David Henry MD Advisory Board
Oliver Sartor MD
Oliver Sartor MD Advisory Board
Barbara Burtness MD
Barbara Burtness MD Advisory Board
See All Experts
featured
Published in Oncology

Expert Opinion / Commentary · March 05, 2014

Progress in NSCLC Molecular Characterization for Personalized Medicine

Jean-Yves Douillard MD, PhD

 

 Save  Recommend
 Share

Additional Info

  1. Douillard JY, Ostoros G, Cobo M, et al. First-line gefitinib in Caucasian EGFR mutation-positive NSCLC patients: a phase IV, open label, single arm study. Br J Cancer. 2014;110(1):55-62.
  2. Diaz LA, Bardelli A. Liquid Biopsies: Genotyping Circulating Tumor DNA [published online ahead of print January 12, 2014]. J Clin Oncol. doi/10.1200/JCO.2012.45.2011.
  3. Oxnard GR, Paweletz CP, Kuang Y, et al. Noninvasive detection of response and resistance in EGFR-mutant lung cancer using quantitative next-generation genotyping of cell-free plasma DNA [published online ahead of print January 15, 2014. Clin Cancer Res. doi: 10.1158/1078-0432.CCR-13-2482.

Further Reading

Most Read This Week

Recently Updated